Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718030 | 0.83 | TSHR (0.37) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL3288843 | 0.79 | TSHR (0.34) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL12855654 | 0.76 | ALDH1A1 (0.47) | TSHRALDH1A1 | |
| SCHEMBL27813107 | 0.76 | THRB (0.41) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL28036354 | 0.76 | ALDH1A1 (0.44) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL4400744 | 0.73 | ALDH1A1 (0.35) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL278164 | 0.73 | — | — | |
| SCHEMBL7127945 | 0.72 | TDP1 (0.52) | TSHRALDH1A1HSD17B10 | |
| SCHEMBL10094791 | 0.71 | ALDH1A1 (0.48) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10094786 | 0.71 | ALDH1A1 (0.48) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123519-A1 | Swellable hydrogel matrix and methods | SURMODICS, INC. | 2009-05-14 | — | — | US | claimed |
| EP-1231950-B1 | HYDROGELS FOR ORTHOPEDIC REPAIR | GENZYME CORP (US) | 2006-06-14 | — | — | EP | claimed |
| US-7008635-B1 | Hydrogels for orthopedic repair | GENZYME CORPORATION (US) | 2006-03-07 | — | — | US | claimed |
| CN-108192098-B | Polyimide precursor composition and use thereof | 长兴材料工业股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-8242179-B2 | Hydrogel-based joint repair system and method | SURMODICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20090226531-A1 | METHODS AND COMPOSITION FOR INTRAOCULAR DELIVERY OF THERAPEUTIC SIRNA | ALLERGAN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090123519-A1 | Swellable hydrogel matrix and methods | SURMODICS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20080021563-A1 | Hydrogel-based joint repair system and method | SURMODICS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002482-A2 | HYDROGEL-BASED JOINT REPAIR SYSTEM AND METHOD | SURMODICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1231950-B1 | HYDROGELS FOR ORTHOPEDIC REPAIR | GENZYME CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060093648-A1 | Hydrogels for orthopedic repair | GENZYME CORPORATION | 2006-05-04 | — | — | US | disclosed |
| US-7008635-B1 | Hydrogels for orthopedic repair | GENZYME CORPORATION (US) | 2006-03-07 | — | — | US | disclosed |
| EP-1231950-A1 | HYDROGELS FOR ORTHOPEDIC REPAIR | FOCAL, INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001017574-A1 | HYDROGELS FOR ORTHOPEDIC REPAIR | FOCAL, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123519-A1 | Swellable hydrogel matrix and methods | MMP26, MMP1, MMP16 | TSHR 3359/4885ALDH1A1 3321/4885TP53 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.